Malin Corporation PLC Immunocore names Head of R&D (1961N)
January 16 2019 - 1:00AM
UK Regulatory
TIDM0Y71
RNS Number : 1961N
Malin Corporation PLC
16 January 2019
Malin Corporation plc
("Malin")
Immunocore names David Berman as
Head of Research & Development
- Malin owns approximately 10% of Immunocore, a Malin Priority Portfolio Asset -
Dublin-Ireland, 16 January 2019: Malin Corporation plc
(ISE:MLC), a company investing in highly innovative life sciences
companies, is pleased to note that Immunocore has named David
Berman as its new Head of Research & Development (R&D).
David joined Immunocore in September 2018 to advance
Immunocore's lead asset, IMCgp100, towards commercialisation and
progress Immuocore's growing pipeline of T Cell Receptor (TCR)
candidates through clinical development. Prior to joining
Immunocore, David was most recently Senior Vice President and Head
of the AstraZeneca Immuno-oncology (IO) Franchise, responsible for
the strategic development and execution of its late-stage IO
programme. David also previously served as Head of the early-stage
oncology progamme at MedImmune, and Head of the Immuno-oncology
exploratory development team at Bristol-Myers Squibb.
"David Berman is an established leader in the field of
immuno-oncology and his appointment as Head of R&D of
Immunocore further demonstrates the potential of the company's
technology pipeline" said Jean-Michel Cosséry, Non-Executive
Director of Malin and Malin's Immunocore Board designate. "With
David's exceptional expertise in developing novel IO targets and
combinations, he is ideally qualified to drive Immunocore's growing
pipeline of TCR candidates through clinical development and
commercialisation."
Malin owns approximately 10% of Immunocore and carried its
investment in Immunocore at EUR85.1 million at 30 June 2018 in its
portfolio fair value estimate under International Private Equity
Valuation guidelines.
A copy of Immunocore's press release is available to view here:
https://www.immunocore.com/news-hub/news
ENDS
For further information, please contact:
Malin
Jessica Bergin, Director of Investor Relations & External
Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Jonathan Birt
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com
Powerscourt (Ireland PR)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
About Malin Corporation plc
Malin (ISE:MLC) is a company investing in highly innovative life
sciences companies. Its purpose is to create shareholder value
through the application of long-term capital and operational and
strategic expertise to a diverse range of global healthcare
businesses. Malin has a focus on innovative businesses underpinned
by exceptional science and works with its investee companies,
providing strategic and financial support to enable them to reach
their value potential. Malin is headquartered and domiciled in
Ireland and listed on Euronext Dublin. For more information visit
www.malinplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDSFFEEIFUSEFF
(END) Dow Jones Newswires
January 16, 2019 02:00 ET (07:00 GMT)
Malin (LSE:0Y71)
Historical Stock Chart
From Apr 2024 to May 2024
Malin (LSE:0Y71)
Historical Stock Chart
From May 2023 to May 2024